Scrape SBIR Bone Repair Patent & Award Database for Phase II Applicants
- Organization
- NSF SBIR Phase II commercialization plan requirement without competitive intelligence tools
- Sector
- SBIR-funded bone repair companies needing competitive analysis for Phase II applications
- Location
- Location unspecified
Source Reference
Executive Context
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Catalyst / Timing
CYTROGEN has SBIR funding but lacks competitive intelligence for their Phase II commercialization plan. Every SBIR biomaterial company faces the same repetitive research burden: manually searching patents and competitor awards to position their technology for Phase II review.
Projected Yield
Proprietary dataset of all SBIR-funded bone repair patents and competing awards
Structural Friction
• Vulnerability: CYTROGEN has SBIR funding but lacks competitive intelligence for their Phase II commercialization plan. Every SBIR biomaterial company faces the same repetitive research burden: manually searching patents and competitor awards to position their technology for Phase II review. • Resource capture: Proprietary dataset of all SBIR-funded bone repair patents and competing awards • Influence capture: First-mover position as the definitive competitive intelligence source for SBIR bone repair companies • Required vectors: Vector: OSINT, Vector: Online Research
Required Capabilities
Vector: OSINT
Primary executor: Phase 1: Patent Status Intelligence: Search USPTO Patent Center for patents filed by Khadijeh Khederlou or assignee CYTR
Vector: Online Research
Supporting vector for: Scrape SBIR Bone Repair Patent & Award Database for Phase II Applicants
Execution Protocol
Execution Protocol Locked
A one-time payment of $19 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.